Begin main content

Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines

Published on: November 28, 2016
Project Number: RC0828-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis?
  2. What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis and non-metastatic prostate cancer receiving adjuvant anti-androgen therapy?
  3. What are the evidence-based guidelines regarding the use of denosumab and zoledronic acid in male patients with osteoporosis?

Key Message

Two evidence-based guidelines were identified that recommend several treatment options for men with osteoporosis to reduce the risk of fracture, including zoledronic acid and denosumab. In one guideline, denosumab is specifically recommended for men with non-metastatic prostate cancer receiving androgen-deprivation therapy and zoledronic acid was highlighted for men with recent hip fracture. Neither guideline reported patient contraindications specific to either drug, although it was stated that bisphosphonates in general should not be used in men with impaired kidney function. No evidence was identified that compared the clinical effectiveness of denosumab with zoledronic acid in men with osteoporosis, including men with non-metastatic prostate cancer.

Tags

osteoporosis, musculoskeletal, denosumab, Prolia, Osteoporosis, Men